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Abstract
Background The effect of intranasal esketamine on cognitive functioning in healthy participants is assessed in this study.
Methods Twenty-four participants (19–49 years) were randomized to one of two treatment sequences in which either esketamine
84 mg or placebo was intranasally administered in a double-blind, two-period crossover design. Primary measures included five
tests of Cogstate® computerized test battery assessed at 1 h predose and 40 min, 2, 4, and 6 h postdose. Secondary measures
included the Mental Effort Scale, Karolinska Sleepiness Scale (KSS), and safety.
Results Esketamine was associated with significant cognitive performance impairment at 40 min postdose for all five Cogstate®
tests (Detection p = 0.0011, Identification p = 0.0006, One-Card Learning p = 0.0040, One Back p = 0.0017, and Groton Maze
Learning Test p < 0.0001) versus placebo. In contrast, performance on these tests did not differ significantly between esketamine
and placebo at 2, 4, or 6 h postdose. Secondary outcomes indicated a significant, transient increase from baseline under
esketamine versus placebo at 40 min postdose on the Mental Effort Scale and at 40 min and 2 h postdose on KSS (p < 0.0001
for both); however, no significant difference was observed on these outcomes between esketamine and placebo at later
timepoints. The most commonly reported adverse events were dizziness (67%), nausea (37.5%), disturbance in attention
(29.2%), and fatigue (29.2%); the majority were considered mild in severity.
Conclusions Esketamine was associated with cognitive performance decline, and greater effort was required to complete the test
battery versus placebo at 40 min postdose, which returned to placebo-comparable levels by 2 h postdose.
Trial registration: ClinicalTrials.gov identifier: NCT02094378
Keywords Cognitive functioning . Cogstate® computerized
test battery . Intranasal esketamine . Treatment-resistant
depression
Introduction
Major depressive disorder (MDD) is a leading cause of disability
worldwide and the most common antecedent illness to suicide
(WHO Fact Sheet, reviewed April 2016). Although many psy-
chopharmacological agents are currently available for the treat-
ment of MDD, a substantial proportion of patients with MDD
are resistant to conventional monoaminergic antidepressants and
more effective interventions are needed for treatment-resistant
depression (TRD). Additionally, patients who do respond to
currently approved antidepressants require up to 4–6 weeks to
show any improvement (Machado-Vieira et al. 2009).
Ketamine, an N-methyl-D-aspartate (NMDA) receptor an-
tagonist, has been reported to exert a rapid onset of antidepres-
sant effect in patients with TRD (Newport et al. 2015).
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Intranasal ketamine has shown safety and efficacy as an anes-
thetic and analgesic agent (Weksler et al. 1993; Louon and
Reddy 1994; Diaz 1997; Weber et al. 2003). Intravenous ke-
tamine has shown impairing effects on cognitive performance
parameters that typically peak following administration and
resolve within a few minutes to up to 2 h after drug discon-
tinuation (Mathew et al. 2010; Murrough et al. 2013a, b;
Zarate et al. 2006).
Several studies have examined cognitive function in infre-
quent and frequent ketamine users (Narendran et al. 2005;
Morgan and Curran 2006; Morgan et al. 2009). Overall, infre-
quent or recreational ketamine use does not appear to be as-
sociated with long-term cognitive impairment (Narendran
et al. 2005). In contrast, frequent ketamine users (more than
five times per week) exhibit impairments in both short- and
long-term memory (Morgan and Curran 2006). Although dos-
ages used have varied, the doses reported by frequent keta-
mine users in this study were much higher than the doses that
have been reported in the literature to alleviate depression
severity in TRD (Newport et al. 2015) and usually used in
combination with other drugs. Memory impairments may be
reversible when individuals stop using the drug, as they were
not found in a group of 30 former ketamine users who had
been abstinent for at least one year (Morgan et al. 2010).
Esketamine (JNJ54135419), the S-enantiomer of ketamine
racemate, has three to four times higher affinity for NMDA
receptors than the R-enantiomer (Himmelseher and
Pfenninger 1998), allowing antidepressant efficacy at lower
doses (Singh et al. 2016). The intranasal route of administra-
tion is generally more convenient than intravenous delivery
and also circumvents the relatively poor bioavailability asso-
ciated with the oral route of administration for ketamine and
esketamine. The relatively rapid onset of action and increased
bioavailability of the drug administered via the intranasal de-
livery route are attributable to the rich vasculature and relative-
ly high systemic absorption of esketamine via the nasal mu-
cosa (Andrade 2015). The absolute bioavailability of intrana-
sal esketamine 20mg and 25mg in healthy participants ranged
between 45 and 59% (Bitter 2011; Yanagihara et al. 2003).
In healthy participants, intranasal esketamine has been rel-
atively well-tolerated (Bitter 2011). However, the potential
effects of intranasal esketamine on cognitive functioning have
not been studied previously. Here, we evaluate the magnitude
and duration of effects on cognitive function of a single dose
of intranasal esketamine 84 mg in healthy volunteers.
Methods
Study population
Healthy men and women aged 19 to 49 years, with a body
mass index 18 to 30 kg/m2 and a body weight of no less
than 45 kg, were recruited into the study. Participants were
excluded if they had systolic blood pressure measurements
less than 90 mmHg or greater than 140 mmHg, diastolic
blood pressure higher than 90 mmHg, or clinically signifi-
cant abnormalities on electrocardiogram. Participants were
also excluded if they had clinically significant medical con-
ditions (including primary sleep disorder), abnormal labora-
tory values or abnormal physical/nasal examination, current
or prior diagnosis of psychosis/psychotic disorder, or perfor-
mance greater than one standard deviation (SD) below the
mean on any of the five tests of the Cogstate® computerized
test battery during the training session.
Study design
This phase 1, double-blind (DB), randomized, placebo-con-
trolled, two-period crossover study was conducted at a single
center in the Netherlands from June 2014 to August 2014
(NCT02094378).
The study consisted of three phases: screening phase (up
to 3 weeks), DB treatment phase (2 weeks), and post-
treatment (follow-up) phase (1 week). During the screening
phase, evaluation of eligibility for participation included two
training sessions on the Cogstate® computerized test battery.
The DB treatment phase consisted of two treatment periods
(periods 1 and 2) separated by a washout interval of at least
7 days. On day 1 of study period 1, participants were ran-
domized to one of two treatment sequences (treatment se-
quence 1: intranasal esketamine 84 mg followed by intrana-
sal placebo; treatment sequence 2: intranasal placebo follow-
ed by intranasal esketamine 84 mg) in a two-way crossover
design (Fig. 1). Randomization was based on a computer-
generated randomization schedule prepared before the study
by or under the supervision of the sponsor. The intranasal
dose of esketamine 84 mg was selected because it produced
a pharmacokinetic profile similar to that of an intravenously
administered esketamine dose of 0.2 mg/kg, which showed
antidepressant effects similar to higher doses of intravenous
esketamine (Singh et al. 2016; Daly et al. 2017). The inves-
tigators, participants, and all study staff were kept blinded to
the assigned treatment at randomization. Methylxanthine-
containing products (chocolate bars, beverages, coffee, teas,
colas, alcohol, etc) were prohibited from 24 h prior to ad-
ministration of study medication.
Assessments
Cognitive functioning measures
The primary endpoint was change in cognitive performance
on each cognitive test from 1 h predose to each postdose
timepoint on day 1 (40 min, 2 h, 4 h, and 6 h) and at 2-h
intervals until participants returned to predose cognitive
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function for each treatment period. Using the Cogstate®
computerized test battery, the study evaluated multiple cog-
nitive domains, including attention, visual and working
memory, and executive functioning. The Cogstate® comput-
erized test battery consists of five tests/scores: Detection,
Identification, One-Card Learning, One Back Memory, and
Groton Maze Learning. The tests use playing card stimuli
and a maze task, enabling use in multilingual/multicultural
settings. Each test has been utilized in earlier drug studies,
and the sensitivity of the Cogstate battery has been validated
across repeated testing and cross-sectional research designs
(Olver et al. 2008; Yoshida et al. 2012; McIntyre et al. 2014;
Shiroma et al. 2014). The difference in each participant’s
performance on any cognitive measure from predose was
based on the Reliable Change Index (RCI), with an absolute
value of RCI ≥ 1.96 considered to be a meaningful change
from the predose score for a test. Participants whose perfor-
mance on any cognitive test had not returned to predose
performance level by 6 h postdose continued cognitive test-
ing at 2-h intervals until all test scores had returned to
predose levels. The criterion for continued testing was any
cognitive test score that in comparison to the predose score
fell in a range defined by the absolute value of |RCI| ≥ 1.96
(i.e., RCI ≤ − 1.96 or RCI ≥ 1.96). The secondary endpoints
were the level of effort needed to complete the Cogstate®
computerized test battery and the level of sleepiness, as
assessed by the change from baseline to each postdose
timepoint on day 1 (40 min, 2 h, 4 h, and 6 h) for each
treatment period using the Mental Effort Scale and the
Karolinska Sleepiness Scale (KSS), respectively.
Safety and tolerability
Safety was evaluated by recording treatment-emergent ad-
verse events (TEAEs), laboratory tests, vital signs, physical
examinations, electrocardiogram monitoring, Columbia
Suicide Severity Rating Scale (C-SSRS), Modified
Observer’s Assessment of Alertness/Sedation (MOAA/S),
Brief Psychiatric Rating Scale (BPRS+), and Clinician
Administered Dissociative States Scale (CADSS).
Additionally, local nasal tolerability was assessed by the
nasal tolerability questionnaire and nasal examination.
Statistical methods
Sample size determination
The sample size was prespecified to 24 participants. Assuming
80% of power and a two-sided significance level of 0.05, with
a sample size of 24 participants, the study was able to detect
the minimal detectable differences between esketamine and
placebo in each cognitive test: Detection: 0.04, Identification:
0.04, One-Card Learning: 0.08, One Back: 0.15, and Groton
Maze Learning Test: 12.87; assuming within-participant SDs
0.06, 0.07, 0.13, 0.25, and 21.5 for the aforementioned five
tests obtained from the healthy control group (n = 120) in a
study comparing the Cogstate® battery and the Measurement
and Treatment Research to Improve Cognition in
Schizophrenia (MATRICS) battery (Pietrzak et al. 2009). A
mixed-effect analysis of variance (ANOVA) model was used
to assess the treatment difference in terms of five tests of the
Cogstate® Computerized Test Battery. The units for these tests
are the mean of log10 transformed reaction times for correct
responses (log 10 ms) on Detection and Identification tests,
arcsine transformation of the proportion of correct responses
for the One-Card Learning test, speed of performance (log 10
ms) for the One Back Test, and total number of errors com-
mitted for the Groton Maze Learning Test.
Analysis set
The intent-to-treat (ITT) or safety analysis set included all
randomized participants who received at least one dose of
study medication during the DB phase.
Fig. 1 Study design and
participant flow
Psychopharmacology (2018) 235:1107–1119 1109
Statistical analyses
Statistical analyses were performed using SAS® version 9.2.
A mixed-effect analysis of variance (ANOVA) model was
applied to each of the five tests of the Cogstate®
Computerized Test Battery to estimate treatment differences
for each timepoint. The model included treatment, period,
gender, and sequence as fixed effects and participants within
sequence as a random effect. Baseline measures of scores
were added as a covariate to the mixed-effect analysis of var-
iance model. For this primary analysis (i.e., five Cogstate®
tests at 40 min), the Hochberg procedure was utilized to con-
trol the family-wise error rate. In addition, for assessing the
learning effect, screening period versus period 1 predose and
screening period versus period 2 predose were examined for
the five Cogstate® tests using paired t tests. To assess sex
effects, a mixed-effect model was applied using repeated mea-
sures (MMRM) with baseline as a covariate, the period, se-
quence, time, sex and sex-by-time interaction as fixed effects,
and the subject as a random effect for each of the five
Cogstate® tests. Mental Effort Scale and KSS were analyzed
using the aforementioned mixed-effect model for the primary
analysis. The incidence of adverse events was summarized by
treatment group.
Results
Participants
All 24 enrolled and randomized participants completed the
study. The demographics and baseline characteristics were
comparable across the groups assigned to treatment sequence
A versus B (Table 1).
Cognitive function measures
Primary cognitive function measures
Compared to predose assessments, cognitive performance
declined to a greater extent under intranasal esketamine
84 mg than under placebo on each test at 40 min postdose
(Table 2). At the 40 min postdose assessment, significant
differences in the least squares (LS) mean (SE) values for
the five Cogstate® tests were noted for placebo versus
esketamine (Fig. 2). The cognitive function in participants
receiving esketamine returned to levels comparable to place-
bo by 2 h postdose. When comparing the two treatment
groups, there was no significant difference between
esketamine 84 mg and placebo in performance on any cog-
nitive test at the 2-, 4-, or 6-h postdose assessments. A total of
seven participants (esketamine: n = 4, placebo: n = 3) had
|RCI| ≤ − 1.96 on at least one cognitive test at 6 h post-treat-
ment, whereas a total of 25 participants (esketamine: n = 14,
placebo: n = 11) met the criteria for continued testing of
RCI ≥ 1.96 on at least one test 6 h post-treatment. Several
participants continued to exhibit performance on a cognitive
test that differed from predose performance through 10 h post
esketamine or placebo, such that four who received
esketamine and two who received placebo continued to per-
form below baseline (i.e., RCI < − 1.96), while ten who re-
ceived esketamine and four who received placebo performed
better than baseline (RCI ≥ 1.96; see Online Resource, sup-
plementary Tables 1 and 2).
Table 1 Demographic and
baseline characteristics Treatment sequence 1
a
n = 12
Treatment sequence 2b
n = 12
Age (years)
Mean (SD) 23.7 (8.07) 27.0 (7.86)
Gender, n (%)
Male 6 (50) 6 (50)
Race, n (%)
White 11 (92) 11 (92)
Other 1 (8) 0
Black or African American 0 1 (8)
Ethnicity, n (%)
Not Hispanic or Latino 10 (83) 12 (100)
Hispanic or Latino 2 (17) 0
BMI (kg/m2)
Mean (SD) 22.7 (2.81) 24.4 (3.67)
BMI body mass index, SD standard deviation
a Intranasal esketamine 84 mg/intranasal placebo
b Intranasal placebo/intranasal esketamine 84 mg
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In order to evaluate potential learning effects, subjects’
performance on each test was evaluated across screening
period versus period 1 predose and screening period versus
period 2 predose. There was no significant difference in
performance on cognitive tests between screening period
versus period 1 predose (Table 3). There were differences
for three tests—Detection (simple reaction time task appears
to be longer at predose period 2 than that at screening peri-
od; LS mean difference = 0.089 and p = 0.006 < 0.05),
Groton Maze Learning (total number of errors appears to
be smaller at predose period 2 than that at screening period;
LS mean difference = − 5.500 and p = 0.010 < 0.05), and
Identification (choice reaction time paradigm appears to be
longer at predose period 2 than that at screening period; LS
mean difference = 0.065 and p = 0.003 < 0.05) between the
screening period and period 2 pre-dose (Table 3). There
were significant differences on performance at the screening
period versus period 2 predose for Detection (p < 0.01),
Groton Maze Learning (p = 0.01), and Identification
(p < 0.01). With respect to gender, a significant difference
was found in One-Card Learning at 40 min in the placebo
group, but performance did not differ significantly between
males and females in the other tests (Supplementary
Table 3).
Secondary cognitive function measures
Mental Effort Scale
Greater effort was required to complete the cognitive test bat-
tery after receiving esketamine versus placebo at the first
postdose time point only (40 min postdose). Mental Effort
Scale LS mean (SE) values at 40 min postdose were placebo:
2.74 (0.35) versus esketamine: 7.01 (0.358), p < 0.0001.
Higher scores indicate greater mental effort required. The
mental effort required to perform the cognitive tests returned
to levels comparable to placebo by 2 h postdose (Fig. 3a), as
the differences between esketamine versus placebo at the 2-,
4-, and 6-h postdose assessments were not statistically
significant.
Karolinska Sleepiness Scale
Increased sleepiness was observed after esketamine adminis-
tration compared to placebo, with significant differences be-
tween groups observed in the KSS at 40min and 2 h postdose,
returning to comparable levels as placebo by 4 h postdose.
The KSS LS mean (SE) values (placebo versus esketamine)
at 40 min postdose were 3.85 (0.344) versus 6.32 (0.344),
p < 0.0001; at 2 h postdose: 3.53 (0.270) versus 5.46
(0.283), p < 0.0001; and at 4 h postdose: 4.14 (0.261) versus
4.27 (0.261), p = 0.72 (Fig. 3b).
Safety
The most frequently reported TEAEs after intranasal
esketamine administration included dizziness (n = 16,
67%), nausea (n = 9, 38%), disturbance in attention, fatigue
and somnolence (n = 7, 29% each), and feeling abnormal
(n = 6, 25%) (Table 4). The majority of TEAEs reported
were rated as mild or moderate in intensity, and all TEAEs
resolved at the end of the study. No deaths or other serious
Table 2 Cognitive Functioning Tests: LS Means (SE) Over Time
Placebo
(N=24)
Esketamine 84 mg
(N=23/24)a
p valueb
Detectionc (Log10 ms)
40 minutesd 2.44 (0.014) 2.51 (0.014) 0.0011
2 hours 2.42 (0.011) 2.43 (0.011) 0.8217
4 hours 2.43 (0.011) 2.41 (0.011) 0.3802
6 hours 2.43 (0.013) 2.40 (0.013) 0.1358
Identificationc (Log10 ms)
40 minutes 2.64 (0.009) 2.68 (0.009) 0.0006
2 hours 2.63 (0.010) 2.63 (0.010) 0.7941
4 hours 2.63 (0.009) 2.62 (0.009) 0.2226
6 hours 2.63 (0.011) 2.60 (0.011) 0.1290
One-Card Learning (arcsine of proportion of correct responses)
40 minutes 1.09 (0.021) 0.99 (0.021) 0.0040
2 hours 1.11 (0.021) 1.07 (0.021) 0.1483
4 hours 1.12 (0.021) 1.10 (0.021) 0.4465
6 hours 1.15 (0.017) 1.15 (0.017) 0.7450
One Back Memoryc (Log10 ms)
40 minutes 2.75 (0.012) 2.80 (0.012) 0.0017
2 hours 2.74 (0.012) 2.76 (0.012) 0.1579
4 hours 2.73 (0.010) 2.74 (0.010) 0.3791
6 hours 2.72 (0.011) 2.72 (0.011) 0.9674
Groton Maze Learning Test (total numbers of errors)
40 minutes 38.5 (2.45) 59.7 (2.51) <0.0001
2 hours 36.7 (2.26) 41.7 (2.31) 0.1250
4 hours 39.6 (2.17) 37.1 (2.17) 0.2986
6 hours 33.6 (1.79) 36.8 (1.79) 0.1422
Detection - speed of performance (Log10 ms), Identification - speed of
performance (Log10 ms), One-Card learning - accuracy of performance,
One Back memory - speed of performance (Log10 ms), Groton Maze
learning test - total numbers of errors, ms - milliseconds
a N=23 in esketamine groups for 40 minutes and 2 hours testing periods,
N=24 for 4 and 6 hours testing periods
b p values (2-sided with level of significance of 5%) are based on the
mixed-effect model with baseline score as a covariate, and treatment,
period, gender and sequence as fixed effects, and subject within sequence
as a random effect
c For these timed tests, higher scores reflect poorer performance
dAll times listed (40 minutes, 2, 4, and 6 hours) reflect the times follow-
ing dosing at which the testing was performed
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Fig. 2 Cognitive function measures mean plots (± SE) for aDetection, b Identification, cOne-Card Learning dOne Back, eGrotonMaze Learning Test
(ITTAnalysis Set)
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TEAEs, or TEAEs leading to discontinuation, occurred in
this study.
The dissociative symptoms assessed using the CADSS
and treatment-emergent psychotic symptoms assessed using
the BPRS+ were reported in participants receiving intranasal
esketamine, with transient increases at 40 min postdose as
compared to placebo, returning to baseline by 2 h postdose
(Fig. 4a, b). Following esketamine administration, more par-
ticipants demonstrated a transient increase in sedation, as
assessed using the MOAA/S, compared to placebo
(esketamine: n = 6; placebo: n = 1) through 4 h postdose.
No dissociative or psychotic symptom and no change in
sedation was reported in participants receiving intranasal
placebo at any time point. No post-baseline change in sui-
cidal ideation or behavior was evident on the CSSR-S in
participants from either group. Overall, no clinically signif-
icant effect on the laboratory parameters, vital signs, or elec-
trocardiogram parameters was observed.
Discussion
This is the first clinical study to evaluate the effects of in-
tranasal esketamine on cognitive functioning. In this explor-
atory study in healthy participants, administration of intrana-
sal esketamine 84 mg was associated with a transient decline
in cognitive function, manifested either as slower perfor-
mance time or greater error rates at 40 min postdosing as
compared to intranasal placebo, but performance returned to
levels comparable to placebo by 2 h postdose. No significant
Fig. 2 (continued)
Psychopharmacology (2018) 235:1107–1119 1113
difference between intranasal esketamine and placebo was
observed at the 2-, 4-, and 6-h timepoints in the LS mean
values for any of the five Cogstate® tests. The transient
reductions in cognitive function in participants receiving in-
tranasal esketamine were associated with early postdose se-
dation, as assessed by the KSS and MOAA/S, and greater
levels of effort required to complete the Cogstate® comput-
erized test battery, as assessed using the Mental Effort Scale.
The increases in sleepiness (at 40 min and 2 h postdose) and
the mental effort required at 40 min post esketamine admin-
istration returned to levels comparable to placebo by 4 and
2 h postdose for mental effort (Fig. 2).
The participant-level data were examined posthoc to as-
sess whether any individuals showed outlying values sug-
gestive of longer-lasting effects. This assessment revealed
that some participants’ performance on cognitive tests had
not returned to predose levels based on RCI criteria at 6 h
post esketamine or longer; however, there were also partic-
ipants whose cognitive test performance had not returned to
predose levels at 6 h post placebo. Some participants con-
tinued to exhibit performance changes versus predose levels
on one or more cognitive tests for up to 10 h postdose after
esketamine or placebo, and these participant level data were
most remarkable for the relatively larger number of partici-
pants whose performance appeared improved relative to
baseline following esketamine (n = 10) versus after placebo
(n = 4). While the potential contribution of fatigue or prac-
tice effects to these outlying values remains unclear, the
apparent numerical difference between conditions in the
numbers of participants showing improved performance at
10 h postdose merits further investigation, particularly in
light of preclinical evidence in rodents that a single admin-
istration of ketamine alters synaptic plasticity in the hippo-
campus and medial prefrontal cortex (Kavalali and
Monteggia 2012; Duman et al. 2016). Further discussion
of participants meeting the RCI criterion for testing beyond
6 h postdose is provided in the Online Resource.
Performance on Detection, Identification, and Groton
Maze Learning tests at period 2, 2 predose differed from
screening, given that Detection and Identification scores de-
clined at period 2 predose but Groton Maze improved, this
is not likely a learning effect. The change from screening to
period 2 predose was less than 1 SD (based on Cogstate test
norms) for each test. The differences may reflect minor var-
iability in cognitive status of some subjects (e.g., perhaps
related to changes in sleep, or mild health ailments). It
should also be considered that subjects’ period 1 experience
in the study may have influenced anticipation/expectations
about period 2. Several recent published reviews of studies
of intravenous ketamine efficacy in MDD have highlighted
that the side effects of ketamine may compromise blinding
of subjects and investigators/raters, thus introducing poten-
tial bias (example, Newport et al. 2015). However, in con-
trast to self- or clinician ratings of mood/symptoms, which
can be subjective, the present study measured cognitive per-
formance via objective cognitive tests; all were computer
administered and scored. The present study did not assess
blinding efficacy, and while it cannot be assured that cogni-
tive performance was unaffected by potential unblinding, as
noted, there was no uniform directionality to the cognitive
performance differences that were observed at period 2
predose versus screening. It will be important that proce-
dures to minimize unblinding are optimized in efficacy trials
of intranasal esketamine treatment for MDD, especially in
regard to clinician ratings. The effect of intranasal
esketamine on increased sleepiness assessed using KSS
was more sustained relative to the effects on cognition,
returning to near baseline levels by 4 h postdose.
Ketamine has been shown to exert a rapid onset of anti-
depressant effect in patients with TRD (Machado-Vieira
et al. 2009; Murrough et al. 2013a, b; Newport et al.
2015; Yang et al. 2015). However, evidence shows that
Table 3 Cognitive Functioning Tests: Comparisons of Screening vs
Predoses (ITTAnalysis Set)
Tests
Screening Predose Period 1
N 24 24
Detection
Mean (SD) 2.40 (0.051) 2.41 (0.062)
p valuea 0.329
Identification
Mean (SD) 2.61 (0.047) 2.61 (0.042)
p value 0.482
One-Card Learning
Mean (SD) 1.09 (0.125) 1.08 (0.120)
p value 0.849
One Back Memory
Mean (SD) 2.76 (0.072) 2.76 (0.086)
p value 0.697
Groton Maze Learning Test
Mean (SD) 38.42 (9.117) 37.00 (14.200)
p value 0.567
p value – predose vs screening
Detection - speed of performance (Log10 ms), Identification - speed of
performance (Log10 ms), One-Card learning - accuracy of performance,
One Back memory - speed of performance (Log10 ms), Groton Maze
learning test - total numbers of errors, ms – milliseconds
a p values (2-sided with level of significance of 5%) and CIs (2-sided) are
based on paired t-test
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ketamine also is associated with acute perceptual and cogni-
tive disturbances following drug administration in healthy
participants as well as in patients with mood disorders
(Krystal et al. 2005; Perry et al. 2007; Murrough et al.
2013a, b). Frequent abuse of high doses of ketamine can
also lead to persistent neurocognitive impairment (Morgan
and Curran 2006; Morgan et al. 2009).
In controlled studies of TRD patients, Murrough et al.
previously reported circumscribed memory impairment im-
mediately following a single ketamine dose (0.5 mg/kg) ad-
ministered as a slow infusion over 40 min (Murrough et al.
2014). In contrast, two studies which explored the
neurocognitive effects of up to six ketamine infusions in
patients with TRD (with unipolar or bipolar depression)
demonstrated no impairment (Diamond et al. 2014;
Shiroma et al. 2014). Shiroma et al. (Shiroma et al. 2014)
demonstrated that serial infusions of ketamine in TRD were
not associated with cognitive decline over 4 weeks. This was
consistent with the study by Diamond et al. (2014), where
no memory deficits were noted after repeated ketamine ad-
ministration, measured 4–7 days as well as 12 and 26 weeks
after the final infusion. In the study by Shiroma et al. (2014)
as well as in the recent study by Murrough et al. (2015),
neurocognitive performance improved following treatment
with intravenous ketamine. However, the studies were lim-
ited by small sample sizes, thus restricting a conclusive anal-
ysis of the relationship between cognitive effects and
ketamine’s antidepressant activity. Also, only the report by
Murrough et al. (2013a, b) assessed ketamine effects on
cognitive function immediately after a single administration
of intravenous ketamine. In the other studies, cognitive as-
sessment was conducted days/weeks following a course of
Fig. 3 Secondary cognitive
function measures mean plots (±
SE) for aMental Effort Scale and
b Karolinska Sleepiness Scale
(ITTAnalysis Set)
Psychopharmacology (2018) 235:1107–1119 1115
ketamine infusions; cognitive effects in the period 40–
60 min post ketamine administration were not assessed. In
the current study, the adverse cognitive effects experienced
by these healthy participants were of short duration and
resolved by 2 h postdose, returning to levels comparable to
those obtained with placebo (Fig. 2). There has been no
previous published report of the effects of intranasal
esketamine on cognitive function in patients with MDD or
on repetitive measurement to assess the time course and
resolution of cognitive changes.
Our observations were substantiated using the Mental
Effort Scale, an assessment of the level of effort needed to
complete the test battery. Reductions in cognitive performance
at 40 min postdose in participants receiving esketamine 84 mg
were associated with a greater level of effort required to com-
plete the test battery. The effect of intranasal esketamine on
increased sleepiness, compared to placebo, as assessed by the
KSS, was more sustained relative to the effects on cognition,
returning to near baseline levels by 4 h postdose. However,
repeated use of some drugs may lead to fewer side effects and
increased tolerance over time, allowing patients to function at
normal, placebo-comparable levels (Verster et al. 2015). It is
yet to be seen if the effects of intranasal esketamine on
reduced cognitive performance and increased sleepiness may
attenuate with more consistent drug use in patients.
Consistent with previous observations obtained during in-
travenous infusion of esketamine in participants with TRD
(Singh et al. 2016), most TEAEs observed following intrana-
sal esketamine were rated mild or moderate in severity. All
TEAEs resolved by the end of the study, and no severe or
serious AE or deaths was reported. No treatment-emergent
abnormal laboratory results or electrocardiogram values were
reported in this study. The single intranasal dose of esketamine
84 mg showed no medically significant safety concerns in
healthy participants. This safety profile was consistent with
that observed in studies of TRD that involved intravenous
ketamine or esketamine administration (aan het Rot et al.
2010; Singh et al. 2016).
The significance of our findings should be evaluated in the
scope of study limitations. The study examined cognitive ef-
fects of only a single dose of intranasal esketamine, in a small
sample of healthy volunteers. While the results contribute to
the understanding of acute intranasal esketamine effects, this
exploratory study is neither designed nor sufficient to enable
conclusions about cognitive safety of intranasal esketamine.
Rather, such conclusions will, at a minimum, require data
from large clinical trials in patients with MDD in which the
cognitive effects of intranasal esketamine are evaluated, in-
cluding cognitive effects during and following both acute
and maintenance treatment. A strength of the study design
was the use of the Cogstate® Battery, which has been validat-
ed against traditional neuropsychological tests (Maruff et al.
2009; Pietrzak et al. 2009) shown to have limited practice
effects at brief test-retest intervals (Collie et al. 2003), and is
sensitive to effects of various drugs on cognitive performance
including ETOH and benzodiazepines (Maruff et al. 2005;
Snyder et al. 2005).
Overall, the results demonstrate that a single dose of intra-
nasal esketamine 84 mg was associated with a decline in cog-
nitive function compared to placebo at 40 min postdose,
which returned to levels comparable to placebo by 2 h
postdose. The reductions in cognitive performance were asso-
ciated with a greater level of effort required to complete the
test battery. Sedation was longer lasting insofar as the drug
versus placebo difference in KSS scores remained statistically
significant at 2 h, but no significant difference in KSS scores
was evident between conditions by 4 h postdose.
Finally, the observation that the number of participants
showing improved performance at 10 h postdose relative to
baseline was larger following esketamine than following pla-
cebo (10 versus 4, respectively) merits investigation in future
studies designed to assess cognitive-enhancing as well as
cognitive-impairing effects, particularly in light of preclinical
evidence that ketamine administration increases synaptic
Table 4 Treatment-emergent adverse events in at least 10% of
participants in any treatment group (safety analysis set)
Esketamine 84 mg
N = 24
Placebo
N = 24
Participants with 1 or more TEAEs 24 (100) 9 (38)
Dizziness 16 (67) 1 (4)
Headache 5 (21) 3 (13)
Disturbance in attention 7 (29) 0
Somnolence 6 (25) 1 (4)
Dysgeusia 3 (13) 1 (4)
Hypoaesthesia 4 (17) 0
Paraesthesia 3 (13) 1 (4)
Fatigue 7 (29) 0
Feeling abnormal 6 (25) 0
Feeling drunk 4 (17) 0
Feeling hot 4 (17) 0
Nausea 9 (38) 0
Vomiting 5 (21) 0
Vision blurred 4 (17) 0
Hallucination, visual 3 (13) 0
Values denoted as n (%). Percentages calculated with the number of
participants in each group as denominator
TEAE treatment-emergent adverse events
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plasticity in the hippocampus and medial prefrontal cortex in
rodent stress models (Kavalali and Monteggia 2012, Duman
et al. 2016). Further clinical testing also is needed to evaluate
the potential differences in esketamine’s effects on cognition
between acute administration versus repeated administration.
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